# Changchun GeneScience Pharmaceutical trials: 112 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 112 trials with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor, 43 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Changchun GeneScience Pharmaceutical Co., Ltd.: 112 rows for $5.60, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/changchun-genescience-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 112
- Recruiting or not yet: 43
- Read on: November 19, 2026

## Trials

The 25 newest of 112, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07936084 | Clinical Trial of GenSci136 in Patients With Myasthenia Gravis | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Patients With MG (gMG and oMG) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936084) |
| September 25, 2026 | NCT07841678 | A Phase III Clinical Study of Jinpei Growth Hormone Injection in the Treatment of Short Stature Children With Small for Gestational Age... | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Small for Gestational Age | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841678) |
| September 14, 2026 | NCT07817615 | A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal... | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817615) |
| August 27, 2026 | NCT07790783 | Phase 1 Clinical Study of GenSci164 Injection | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Adult Trial Participants | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790783) |
| July 8, 2026 | NCT07691125 | Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 4 | Recruiting | Short Bowel Syndrome (SBS) in Adults | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691125) |
| July 6, 2026 | NCT07685210 | GenSci144 Tablets Phase I Clinical Trial | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Phenylketonuria | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685210) |
| June 23, 2026 | NCT07663838 | A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and... | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Randomized, Open-label, Safety, Tolerability, Pharmacokinetics, Bacterial Vaginosis | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663838) |
| June 10, 2026 | NCT07638800 | Phase 1 Clinical Study of GenSci155 Injection in Healthy Adults | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Adult Trial Participants | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638800) |
| April 28, 2026 | NCT07553728 | Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART) | Changchun GeneScience Pharmaceutical Co., Ltd. | Observational | Recruiting | Infertility | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553728) |
| April 23, 2026 | NCT07547995 | A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis. | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Uveitis | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547995) |
| April 17, 2026 | NCT07537231 | A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral \[14C\]GS1-144 in Healthy Postmenopausal Female Participants | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Healthy Postmenopausal Women, Absorption, Metabolism, Excretion | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537231) |
| April 16, 2026 | NCT07534176 | To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets . | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Completed | Postmenopause | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07534176) |
| March 24, 2026 | NCT07491289 | GS1-144 in Participants With Hepatic Impairment and Healthy Female | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Hepatic Impairment and Healthy Female | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07491289) |
| March 17, 2026 | NCT07476586 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Healthy Volunteers | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476586) |
| March 16, 2026 | NCT07473570 | A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Adults | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473570) |
| March 4, 2026 | NCT07450053 | A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Idiopathic Short Stature | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07450053) |
| March 4, 2026 | NCT07450001 | A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Pediatric Growth Hormone Deficiency | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07450001) |
| February 20, 2026 | NCT07423533 | Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who... | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Rheumatoid Arthritis | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423533) |
| February 12, 2026 | NCT07407504 | GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors. | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407504) |
| January 26, 2026 | NCT07366866 | A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Autoimmune Disease | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07366866) |
| January 21, 2026 | NCT07356037 | Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Cachexia, Hepatocellular Carcinoma | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356037) |
| December 24, 2025 | NCT07302035 | A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Bacterial Vaginosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07302035) |
| December 16, 2025 | NCT07286656 | A Study of GensSci098 in Subjects With Graves' Disease | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Safety, Tolerability, GenSci098, Graves Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286656) |
| December 4, 2025 | NCT07264595 | A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD) | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Pediatric Growth Hormone Deficiency | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07264595) |
| December 3, 2025 | NCT07260500 | A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Short Stature Children Born Small for Gestational Age (SGA) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260500) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 47 |
| Phase 1/2 | 6 |
| Phase 2 | 18 |
| Phase 3 | 22 |
| Phase 4 | 10 |
| Not applicable | 3 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 33 |
| Recruiting | 27 |
| Unknown | 25 |
| Not yet recruiting | 16 |
| Active not recruiting | 6 |
| Terminated | 4 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dwarfism, Pituitary | 13 |
| Dwarfism | 4 |
| Infertility | 4 |
| Cachexia | 2 |
| Carcinoma, Hepatocellular | 2 |
| Turner Syndrome | 2 |
| Arthritis, Rheumatoid | 2 |
| Hyperprolactinemia | 2 |
| Autoimmune Diseases | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Vaginosis, Bacterial | 2 |
| Digestive System Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Phenylketonurias | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Arthritis, Juvenile | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Myelodysplastic Syndromes | 1 |
| Short Bowel Syndrome | 1 |
| Uveitis | 1 |
| Graves Disease | 1 |
| Prader-Willi Syndrome | 1 |
| Neoplasm Metastasis | 1 |
| Gout | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Education services in the United States](https://specstream.ai/data/businesses/education-services/united-states)
- [Family practice clinics in the United States](https://specstream.ai/data/businesses/family-practice-clinics/united-states)
- [Gastroenterology practices in the United States](https://specstream.ai/data/businesses/gastroenterology-practices/united-states)
- [Home staging companies in the United States](https://specstream.ai/data/businesses/home-staging-companies/united-states)
- [Inventory control companies in the United States](https://specstream.ai/data/businesses/inventory-control-companies/united-states)
